Atea Pharmaceuticals
AVIR
143 hedge funds and large institutions have $477M invested in Atea Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 47 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 35
11% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $14.2M
2% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 47
1% more funds holding
Funds holding: 142 → 143 (+1)
4.15% less ownership
Funds ownership: 68.67% → 64.52% (-4.2%)
76% less capital invested
Capital invested by funds: $1.99B → $477M (-$1.52B)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$83.8M |
| 2 |
BlackRock
New York
|
+$25.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.5M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$23.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$190M |
| 2 |
PA
Perceptive Advisors
New York
|
-$79.2M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$58M |
| 4 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$57.4M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$50.6M |
AVIR Hedge Fund Activity: Q4 2021 in Review
143 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q4 2021, worth a combined $477M — down 76% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new AVIR positions and 47 closed out — a net gain of 1 holder — while 47 added to existing stakes and 35 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $83.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $190M sold.
- 143 institutional investors held Atea Pharmaceuticals (AVIR) as of Q4 2021, up from 142 in Q3 2021.
- Funds reported $477M of Atea Pharmaceuticals stock for Q4 2021, down 76% quarter-over-quarter.
- 48 funds opened new Atea Pharmaceuticals positions in Q4 2021 and 47 closed out, a net change of +1 holder.
- The largest Atea Pharmaceuticals buyer in Q4 2021 was EcoR1 Capital, an estimated $83.8M added.
- The largest Atea Pharmaceuticals seller in Q4 2021 was RA Capital Management, an estimated $190M sold.
Based on aggregated 13F filings for Q4 2021.